ReviewMolecular therapy : the journal of the American Society of Gene Therapy2024
mRNA-based therapeutic strategies for cancer treatment.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Rapid growth and thematic shifts in mRNA therapeutics research catalyzed by the COVID-19 pandemic.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy.Journal of nanobiotechnology · 2026Review
- Engineering biopolymer nanoparticles for targeted nanomedicine in cancer therapy and food preservation.Frontiers in nutrition · 2026Review
- Spectral fingerprint diagnosis: Spatially independent analysis of biomarker patterns in homogeneous systems.Science advances · 2025Article
- Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions.Blood advances · 2025Review
- Cyclodextrin-Based Formulations as a Promising Strategy to Overcome the Blood-Brain Barrier: Historical Overview and Prospects in Glioblastoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A cohort of mRNAs undergo high-stoichiometry NSUN6-mediated site-specific mNature communications · 2025Article
- Expanding horizons of cancer immunotherapy: hopes and hurdles.Frontiers in oncology · 2025Review
- Recent Advances in Targeted Nanocomposite-based Therapeutics for Cancer Therapy.Current drug research reviews · 2025Review
- Oligonucleotide therapeutics in sports? An antidoping perspective.Archiv der Pharmazie · 2025Review
- Construction of Nanotube-Shaped mRNA Vehicles Using Self-Assembling Peptides.Methods in molecular biology (Clifton, N.J.) · 2025Article
- The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems.Pharmaceutics · 2024Review
- Staying on target in gene and cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the rapidly evolving landscape of medical research, the emergence of RNA-based therapeutics is paradigm shifting. It is mainly driven by the molecular adaptability and capacity to provide precision in targeting. The coronavirus disease 2019 pandemic crisis underscored the effectiveness of the mRNA therapeutic development platform and brought it to the forefront of RNA-based interventions. These RNA-based therapeutic approaches can reshape gene expression, manipulate cellular functions, and correct the aberrant molecular processes underlying various diseases. The new technologies hold the potential to engineer and deliver tailored therapeutic agents to tackle genetic disorders, cancers, and infectious diseases in a highly personalized and precisely tuned manner. The review discusses the most recent advancements in the field of mRNA therapeutics for cancer treatment, with a focus on the features of the most utilized RNA-based therapeutic interventions, current pre-clinical and clinical developments, and the remaining challenges in delivery strategies, effectiveness, and safety considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.